<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003490</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066529</org_study_id>
    <secondary_id>CCF-IRB-1863</secondary_id>
    <secondary_id>IMMUNEX-001.0743</secondary_id>
    <secondary_id>NCI-V98-1458</secondary_id>
    <nct_id>NCT00003490</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma</brief_title>
  <official_title>Phase II to Treat Multiple Myeloma Patients With Cytoxan and Vincristine After Cycling Myeloma Cells With rHuGM-CSF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. GM-CSF may make cancer cells more sensitive to the effects of&#xD;
      chemotherapy. Combining more than one drug with GM-CSF may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, consisting of&#xD;
      cyclophosphamide plus vincristine, following GM-CSF in treating patients with multiple&#xD;
      myeloma that has not responded to previous treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the response rate of multiple myeloma patients when treated with&#xD;
      cyclophosphamide and vincristine after cycling myeloma cells with sargramostim (GM-CSF). II.&#xD;
      Evaluate whether Labelling Index (LI) changes influenced by GM-CSF would predict a group of&#xD;
      patients that will respond to this particular course specific design. III. Determine the&#xD;
      toxicity of GM-CSF in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive subcutaneous injections of sargramostim (GM-CSF) once a day for 5&#xD;
      days. Two to 3 days later, patients receive cyclophosphamide IV over 30-45 minutes on day 1,&#xD;
      vincristine IV bolus on day 8, and oral prednisone 4 times a day on days 1-4. Patients also&#xD;
      receive subcutaneous injections of GM-CSF starting on day 2 and continuing for 10 days or&#xD;
      until neutrophil count is at least 1000/mm3. Treatment continues every 3 weeks for a minimum&#xD;
      of 6 courses in the absence of disease progression or unacceptable toxicity. Patients who&#xD;
      achieve at least stable response receive GM-CSF 3 times a week for up to 2 years. Patients&#xD;
      are followed every 3-6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 30 patients will be accrued.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1998</start_date>
  <completion_date type="Actual">August 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven multiple myeloma Pancytopenia related to&#xD;
        multiple myeloma allowed Failed or progressed after at least 2 chemotherapy or biologic&#xD;
        therapy regimens&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: Not specified Life&#xD;
        expectancy: Not specified Hematopoietic: Platelet count at least 50,000/mm3 Absolute&#xD;
        neutrophil count at least 750/mm3 Hepatic: SGOT/SGPT less than 3 times upper limit of&#xD;
        normal Bilirubin less than 5.0 mg/dL Renal: Not specified Other: No active infection&#xD;
        requiring intravenous antibiotics Not HIV positive Not pregnant or nursing Fertile patients&#xD;
        must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics May have failed&#xD;
        prior bone marrow transplant No other concurrent colony stimulating factors Concurrent&#xD;
        immunoglobulin allowed Chemotherapy: See Disease Characteristics Concurrent pamidronate&#xD;
        allowed Endocrine therapy: Not specified Radiotherapy: Concurrent standard radiation&#xD;
        therapy to treat extra-skeletal and/or skeletal tumor sites allowed Surgery: Not specified&#xD;
        Other: Concurrent epoetin alfa for anemia allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamad A. Hussein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2001</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 20, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2004</study_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

